Company Overview and News
Plantation sector Maintain neutral: The Malaysia Palm Oil Board’s September 2018 palm oil stocks increased slightly by 1.4% month-on-month (m-o-m) to 2.54 million tonnes versus market expectations of a decline of between 0.6% and 1.4%. The deviation was mainly due to a lower-than-expected rise in exports (+47.2% m-o-m) and lower domestic usage (-20.6% m-o-m). Note that the market was expecting an increase in exports of 50%.
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719
KUALA LUMPUR (Sept 27): United Malacca Bhd shares fell 2.28% this morning after it registered a higher net loss of RM18.49 million for the first financial quarter ended July 31, 2018 (1QFY19) from RM316,000 a year ago, on lower production of fresh fruit bunches but expects production to improve in the second half. Even so, it warned of challenges in the financial year owing to depressed crude palm oil prices and the adoption of a new accounting framework.
In the notes to its financial statements, the company said its losses were mainly due to low FFB yield from both Malaysian and Indonesian operations, lower average prices of crude palm oil and palm kernel by 13% and 15% respectively.
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF
KUALA LUMPUR (Sept 26): United Malacca Bhd registers a higher net loss of RM18.49 million for the first financial quarter ended July 31, 2018 (1QFY19) from RM316,000 a year ago, on lower production of fresh fruit bunches (FFB) but expects production to improve in the second half. Even so, it warned of challenges in the financial year owing to depressed crude palm oil (CPO) prices and the adoption of a new accounting framework.
KUALA LUMPUR (Aug 14): The FBM KLCI reversed its earlier losses and clawed into positive territory at mid-morning today, lifted by select blue chips including Tenaga Nasional Bhd.
APEXF 7090 8621 5681 7248 6033 2593 7079 PNADF 5347 5225 8613 6645 TNABY TNABF Q0F IHHHF PNAGF
KUALA LUMPUR, Aug 10 — Bursa Malaysia bucked the trend of most of its Asian peers to stay in positive territory at mid-afternoon today on higher crude oil prices.
0143 PNADF 0026 UPBMF 7036 5681 BSMAF PNAGF 2089 6033 1818 2593
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...